Table 3. Different NA therapies in HCC and control groups.
HCC< (n = 57) | Non-HCC (n = 57) | |
---|---|---|
Entecavir | 38 (66.7%) | 50 (87.7%) |
Lamivudine | 9 (15.8%) | 3 (5.3%) |
Telbivudine | 1 (1.8%) | 1 (1.8%) |
Adefovir | 6 (10.5%) | 2 (3.5%) |
Tenofovir | 3 (5.3%) | 1 (1.8%) |
NA, nucleos(t)ide analogue; HCC, hepatocellular carcinoma.